Mahkam Zanganeh compensation by year
Summit Therapeutics Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $49,615 | $450,000 | $450,000 | $600,000 | $600,000 | $616,500 |
| Bonus | $0 | $182,250 | $452,500 | $0 | $540,000 | $388,395 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $476,316 | $8,987,768 | $307,200 | $19,905,115 | $0 | $245,021,384 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,381 | $19,196 | $32,349 | $57,809 | $21,021 | $21,000 |
| Total | $527,312 | $9,639,214 | $1,242,049 | $20,562,924 | $1,161,021 | $246,047,279 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Summit Therapeutics Inc. DEF 14A filed April 17, 2026, accession 0001599298-26-000029, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Summit Therapeutics Inc. filed document, accession 0001599298-26-000029. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 3,196,053 | — | $1.68 |
| Option | 346,580 | — | $1.06 |
| Option | 5,994,099 | — | $1.68 |
| Option | 133,300 | — | $1.29 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Summit Therapeutics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 17, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-12 | Purchase | — | 3,810,000 | $13.12 | 573,883,879 |
| 2026-06-04 | Purchase | — | 100,000 | $14.60 | 25,824,474 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Summit Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Manmeet Soni | Chief Operating Officer, Chief Financial Officer and Director | $249,127,782 |
| Mahkam Zanganeh · this page | Co-Chief Executive Officer, President and Director | $246,047,279 |
| Robert Duggan | Co-Chief Executive Officer and Chairman of the Board of Directors | $172,376 |
Board service
Summit Therapeutics board · FY2021–FY2025How this board is paid
Company policy: Summit Therapeutics pays directors a $49,900 cash retainer and $35,000 in Options. As stated in Summit Therapeutics's FY2025 proxy.
The full Summit Therapeutics compensation record
free company briefThis page is one person within Summit Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Summit Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Summit Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order SMMT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.